Home Policy Priorities Health Life Sciences

Life Sciences

Data-driven policy promoting innovation and access. 

Life Sciences

About Life Sciences

Pioneer’s Life Sciences Initiative (PLSI) is a nationally recognized authority on life sciences policy, working in Washington, D.C., and in more than 20 states. Leveraging a team of experts from around the country, PLSI strengthens the policies that drive biomedical innovation and expand patient access.  

Our work draws on extensive experience with QALY analysis, economic modeling, patent protections, FDA pathways, gene therapies, pricing and price controls, pharmacy benefit managers, out-of-pocket affordability issues, and federal drug pricing programs such as 340B.  

Informed by deep expertise in regions like Massachusetts—home to the world’s leading life sciences cluster—where industry, universities, hospitals, and nonprofits come together to advance discovery and set standards for excellence, we aim to keep the United States a global leader in developing breakthrough therapies and ensuring patients have access to them. 

May 9, 2025

Pioneer Institute Launches Tracker Showing Drug Price Controls Are Raising Out-of-Pocket Costs for Medicare Patients

A new data tool from Pioneer Institute reveals that federal drug price controls—intended to reduce out-of-pocket costs for seniors—are instead making many prescription drugs more expensive for Medicare beneficiaries.  
January 23, 2025

Pioneer Institute Study Calls for Reforms to Ensure that Pharmacy Benefit Manager Practices Benefit Patients, Healthcare Payers

Congress likely to take up PBM reform early this year; Pioneer Institute Calls for PBM’s to be more transparent

An Evaluation of 340B in Massachusetts

Despite the fact that the 340B Drug Pricing Program has expanded immensely in recent years, the amount of charity care that hospitals are providing has decreased. This points to several problems with the 340B program across the country and in Massachusetts, such as a lack of transparency and inaccessible care.
January 22, 2024

‘High’ U.S. Drug Prices Mask Freeloading by Other Nations

The drug company’s choice is to walk away from millions in revenue from a given country and deny their people a lifesaving drug, or swallow hard and accept an unfair price that is nowhere near the drug’s value. For the sake of shareholders and patients, drug companies typically accept the unfair price and devote the revenue to offsetting their previous investments. In short, other nations are freeloading off of American R&D.

Support Pioneer

Philanthropic support fuels our ability to deliver bold ideas, rigorous research, and real-world impact—advancing solutions that shape policy and strengthen communities.

Want to get the latest updates from Pioneer Institute?

Sign Up For Our Newsletter

Name(Required)
Email(Required)

Electricity Generation by State: 2023

How much electricity do states produce? In 2023, Texas generated twice as much power as Florida, the next closest state. At the other end of the spectrum, Vermont produced the least electricity and had the lowest per capita generation rate. Explore the data on US DataLabs! https://loom.ly/-trkbR4
#facts#electricitygeneration